Georgia Mitropoulou

Dr. Georgia Mitropoulou

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2022 in European Respiratory Review
Verified
Journal Article
Open access
PDF file
GMGeorgia Mitropoulou
Georgia Mitropoulou
AKAngela Koutsokera
Angela Koutsokera
CCChantal Csajka
Chantal Csajka
SBSylvain Blanchon
Sylvain Blanchon
ASAlain Sauty
Alain Sauty
BGBenoit Guery
Benoit Guery
Lower respiratory tract infections lead to significant morbidity and mortality. They are increasingly caused by multidrug-resistant pathogens, notably in individuals with cystic fibrosis, hospital-acquired pneumonia and lung transplantation. The use of bacteriophages (phages) to treat bacterial infections is gaining growing attention, with numerous published cases of compassionate treatment over the last few years. Although the use of phages appears safe, the lack of standardisation, the significant heterogeneity of published studies and the paucity of robust efficacy data, alongside regulatory hurdles arising from the existing pharmaceutical legislation, are just some of the challenges phage therapy has to overcome. In this review, we discuss the lessons learned from recent clinical experiences of phage therapy for the treatment of pulmonary infections. We review the key aspects, opportunities and challenges of phage therapy regarding formulations and administration routes, interactions with antibiotics and the immune system, and phage resistance. Building upon the current knowledge base, future pre-clinical studies using emerging technologies and carefully designed clinical trials are expected to enhance our understanding and explore the therapeutic potential of phage therapy.

8 January 2020 in Respiration
Verified
Journal Article
Closed access
PDF file
GMGeorgia Mitropoulou
Georgia Mitropoulou
CDCécile Daccord
Cécile Daccord
ASAlain Sauty
Alain Sauty
APAntoine Pasche
Antoine Pasche
BEBernard Egger
Bernard Egger
RLRomain Lazor
Romain Lazor
Immune checkpoint inhibitors (ICIs) have been shown to improve overall and progression-free survival in various cancers but have been associated with various immune-related adverse events (IRAEs), including interstitial lung disease, especially organizing pneumonia. We report 2 cases of isolated severe airway disease attributable to ICIs, a rarely reported pattern of lung toxicity. The first patient received nivolumab with or without ipilimumab in a randomized double-blind trial for locoregional metastatic melanoma. The second patient was treated with nivolumab for lung adenocarcinoma. An IRAE was suspected in both cases due to a temporal relationship between ICI initiation and symptom onset. ICIs were stopped, and high-dose prednisone, inhaled corticosteroids, and bronchodilators were administered, allowing a rapid clinical and functional improvement in Patient 1. In Patient 2, despite prolonged high-dose prednisone, only a stabilization of forced expiratory volume in 1 s could be achieved, and the disease course was complicated by respiratory infections resulting in further loss of lung function. The patient died 1 year later due to progression of metastatic disease. These 2 cases suggest that pulmonary IRAEs secondary to ICIs may present as isolated bronchitis or bronchiolitis, with variable outcomes following ICI withdrawal and systemic corticosteroids.

24 November 2022 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
GMGeorgia Mitropoulou
Georgia Mitropoulou
NBNathalie Brandenberg
Nathalie Brandenberg
SHSylke Hoehnel
Sylke Hoehnel
CCCamilla Ceroni
Camilla Ceroni
ZBZisis Balmpouzis
Zisis Balmpouzis
AKAngela Koutsokera
Angela Koutsokera

1 February 2023 in Respiration
Verified
Journal Article
Open access
PDF file
GMGeorgia Mitropoulou
Georgia Mitropoulou
RHRaphael Heinzer
Raphael Heinzer
JJJean-Paul Janssens
Jean-Paul Janssens
CGChristophe von Garnier
Christophe von Garnier
MPMaura Prella
Maura Prella
Background: Mechanical insufflation/exsufflation (MI-E) devices are often prescribed to patients with inefficient cough and recurrent infections, but their use in the home setting is not well characterized. Objective: The objective of this study was to report a real-life experience and identify factors that are associated with home MI-E use in adult patients. Methods: This is a cross-sectional observational study of adult subjects with neurological disease using MI-E at home for more than 3 months. Results: A total of 43 patients were included. Median age (interquartile range) was 48 (31–64) years. The most common diagnosis was muscular dystrophy (n = 15), followed by multiple sclerosis (n = 7) and amyotrophic lateral sclerosis (n = 7). 24 subjects (56%) reported using the MI-E at least once weekly. Based on device data downloads, the median objective use was 23% of days analysed (approximately 2 times per week). The vast majority (94%) of all participants reported using the device at least daily during an infectious episode, while 62% reported having used the device in emergency situations such as bronchoaspiration. Reported use correlated well with objective use (r = 0.82). Most subjects reported an improvement in their respiratory health (64%) and were satisfied with the device (78%). Higher reported and objective use were associated with increased symptoms (p = 0.001) and higher satisfaction with the device (p = 0.008). We found no association between frequency of use and baseline cough peak flow (CPF), bulbar impairment, non-invasive ventilation use, living environment, or supervised administration. Conclusion: Regular home MI-E use was associated with greater symptom burden and overall satisfaction with the device and was not influenced by baseline CPF. Patients without substantial bronchorrhea might not use the MI-E regularly but might still need to use the device at home during acute events. Therefore, familiarity with the MI-E via appropriate and repeated practical training is crucial.

8 November 2022 in Respiratory Medicine Case Reports
Verified
Journal Article
Open access
ZBZisis Balmpouzis
Zisis Balmpouzis
ARAnnabelle Faure van Rossum
Annabelle Faure van Rossum
DBDavid Baud
David Baud
Alice PanchaudAlice Panchaud
Alice Panchaud
GMGeorgia Mitropoulou
Georgia Mitropoulou
AKAngela Koutsokera
Angela Koutsokera
Before the arrival of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators women with CF and impaired lung function were experiencing a high risk of complications and mortality during and the years after pregnancy. The arrival of the highly efficient CFTR modulator, Elexacaftor-Tezacaftor-Ivacaftor (ETI) resulted in an improvement of lung function, quality of life and fertility. Here we report a case of successful pregnancy and uncomplicated delivery for a CF patient with severely impaired lung function receiving ETI prior to conception.

1 November 2022 in Respiratory Medicine and Research
Verified
Journal Article
Closed access
GMGeorgia Mitropoulou
Georgia Mitropoulou
ZBZisis Balmpouzis
Zisis Balmpouzis
JPJérôme Plojoux
Jérôme Plojoux
JDJennifer Dotta-Celio
Jennifer Dotta-Celio
ASAlain Sauty
Alain Sauty
AKAngela Koutsokera
Angela Koutsokera